Investigational Drug Information for Camptothecin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Camptothecin?
Camptothecin is an investigational drug.
There have been 146 clinical trials for Camptothecin.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2006.
The most common disease conditions in clinical trials are Neoplasms, Adenocarcinoma, and Colorectal Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Astex Pharmaceuticals, and Astex Pharmaceuticals, Inc.
Summary for Camptothecin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,963 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 108 |
| Clinical Trial Progress | Phase 3 (2006-07-01) |
| Vendors | 95 |
Recent Clinical Trials for Camptothecin
| Title | Sponsor | Phase |
|---|---|---|
| FOLFIRINOX + NIS793 in Pancreatic Cancer | Novartis | Phase 1 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer | Colin D. Weekes, M.D. | Phase 1 |
| EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | Ellipses Pharma | Phase 2 |
Clinical Trial Summary for Camptothecin
Top disease conditions for Camptothecin
Top clinical trial sponsors for Camptothecin
US Patents for Camptothecin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
